Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2025)

Historic Long-Term Investments for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to $473.1 million.

  • Kymera Therapeutics' Long-Term Investments rose 3103.99% to $473.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $473.1 million, marking a year-over-year increase of 3103.99%. This contributed to the annual value of $362.2 million for FY2024, which is 48957.58% up from last year.
  • Kymera Therapeutics' Long-Term Investments amounted to $473.1 million in Q3 2025, which was up 3103.99% from $297.6 million recorded in Q2 2025.
  • Kymera Therapeutics' Long-Term Investments' 5-year high stood at $473.1 million during Q3 2025, with a 5-year trough of $45.3 million in Q2 2021.
  • Its 5-year average for Long-Term Investments is $175.4 million, with a median of $113.7 million in 2022.
  • Per our database at Business Quant, Kymera Therapeutics' Long-Term Investments crashed by 6015.23% in 2021 and then surged by 48957.58% in 2024.
  • Kymera Therapeutics' Long-Term Investments (Quarter) stood at $125.2 million in 2021, then increased by 21.67% to $152.3 million in 2022, then plummeted by 59.67% to $61.4 million in 2023, then soared by 489.58% to $362.2 million in 2024, then soared by 30.62% to $473.1 million in 2025.
  • Its Long-Term Investments stands at $473.1 million for Q3 2025, versus $297.6 million for Q2 2025 and $312.3 million for Q1 2025.